Your browser is no longer supported. Please, upgrade your browser.
Genprex, Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own17.55% Shs Outstand39.06M Perf Week-0.53%
Market Cap166.13M Forward P/E- EPS next Y-3.68 Insider Trans0.00% Shs Float35.50M Perf Month11.28%
Income-15.10M PEG- EPS next Q-0.28 Inst Own23.40% Short Float8.90% Perf Quarter3.59%
Sales- P/S- EPS this Y26.00% Inst Trans43.29% Short Ratio2.75 Perf Half Y22.95%
Book/sh0.59 P/B6.36 EPS next Y-569.10% ROA-79.40% Target Price- Perf Year941.67%
Cash/sh0.48 P/C7.87 EPS next 5Y- ROE-81.30% 52W Range0.33 - 7.03 Perf YTD-9.64%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.66% Beta-
Dividend %- Quick Ratio58.60 Sales past 5Y- Gross Margin- 52W Low1045.04% ATR0.34
Employees8 Current Ratio60.50 Sales Q/Q- Oper. Margin- RSI (14)47.22 Volatility6.63% 10.99%
OptionableYes Debt/Eq0.00 EPS Q/Q52.70% Profit Margin- Rel Volume0.81 Prev Close3.83
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.15M Price3.75
Recom2.00 SMA20-8.73% SMA504.75% SMA20012.96% Volume926,244 Change-2.09%
Apr-29-19Initiated Noble Capital Markets Outperform $5
Jan-14-21 08:30AM  
Jan-13-21 09:00AM  
Dec-24-20 01:02PM  
Dec-23-20 12:40PM  
Dec-22-20 01:15PM  
Dec-17-20 08:47AM  
Dec-08-20 08:16AM  
Dec-03-20 08:17AM  
Nov-30-20 02:05PM  
Nov-24-20 09:30AM  
Nov-11-20 08:16AM  
Nov-10-20 08:17AM  
Oct-30-20 08:17AM  
Oct-29-20 08:16AM  
Oct-26-20 08:16AM  
Oct-07-20 08:17AM  
Oct-06-20 08:16AM  
Sep-21-20 08:17AM  
Sep-09-20 04:25PM  
Sep-02-20 05:36PM  
Aug-26-20 08:17AM  
Aug-05-20 03:34PM  
Jul-31-20 08:17AM  
Jul-30-20 08:16AM  
Jul-21-20 12:58PM  
Jun-29-20 08:16AM  
Jun-25-20 08:17AM  
Jun-24-20 08:16AM  
Jun-16-20 08:17AM  
Jun-09-20 08:17AM  
Jun-08-20 08:17AM  
May-28-20 08:17AM  
May-05-20 01:00PM  
May-04-20 08:17AM  
Apr-21-20 08:17AM  
Mar-24-20 08:17AM  
Mar-23-20 08:17AM  
Mar-05-20 08:05AM  
Mar-04-20 08:00AM  
Mar-03-20 08:17AM  
Feb-21-20 04:15PM  
Feb-20-20 10:22AM  
Feb-19-20 09:23AM  
Feb-11-20 08:17AM  
Feb-06-20 08:17AM  
Feb-05-20 09:00AM  
Feb-03-20 08:17AM  
Jan-29-20 08:18AM  
Jan-28-20 08:00AM  
Jan-24-20 07:00AM  
Jan-23-20 09:00AM  
Jan-22-20 10:54AM  
Jan-21-20 08:00AM  
Jan-06-20 08:00AM  
Nov-20-19 11:15AM  
Nov-19-19 08:00AM  
Nov-04-19 08:00AM  
Oct-15-19 08:00AM  
Oct-09-19 08:00AM  
Oct-07-19 08:00AM  
Sep-26-19 08:30AM  
Sep-25-19 08:30AM  
Sep-18-19 08:00AM  
Sep-11-19 08:00AM  
Sep-07-19 04:35PM  
Sep-06-19 08:30AM  
Sep-04-19 01:43PM  
Aug-23-19 08:30AM  
Aug-22-19 08:30AM  
Aug-21-19 03:31PM  
Aug-13-19 08:00AM  
Aug-06-19 08:00AM  
Jul-31-19 08:30AM  
Jul-09-19 01:58PM  
Jul-01-19 08:30AM  
May-31-19 08:30AM  
May-30-19 08:35AM  
May-21-19 08:30AM  
May-09-19 08:30AM  
May-08-19 08:30AM  
Apr-12-19 09:00AM  
Apr-11-19 08:30AM  
Apr-08-19 08:30AM  
Apr-01-19 08:30AM  
Mar-29-19 09:00AM  
Mar-28-19 08:30AM  
Genprex, Inc. operates as a clinical-stage gene therapy company that develops therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes. It develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate REQORSA (quaratusugene ozeplasmid) for treatment for non-small cell lung cancer (NSCLC) has a multimodal mechanism of action to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis and programmed cell death in cancer cells; modulate immune response against cancer cells; and block mechanisms that create drug resistance. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.